Actively Recruiting

Phase 3
Age: 12Months - 12Years
All Genders
Healthy Volunteers
NCT07054099

A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years

Led by GC Biopharma Corp · Updated on 2026-04-17

474

Participants Needed

1

Research Sites

537 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This clinical study aims to evaluate the safety and immune response of MG1111, in healthy children compared to VARIVAX. The study will follow participants for 42 days after receiving two doses, with additional follow-ups for up to 10 years to monitor varicella infection.

CONDITIONS

Official Title

A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years

Who Can Participate

Age: 12Months - 12Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Participant must be 12 months to 12 years of age, inclusive, at the time of signing the informed consent or assent
  • Participant is overtly healthy as determined by the investigator
Not Eligible

You will not qualify if you...

  • Participants with a history of exposure to varicella through contact with a varicella patient at home, school, or childcare facility within 4 weeks before Screening
  • Participants with a history of varicella infection and varicella vaccine, either licensed or investigational, and either standalone or any combination, such as MMRV
  • Participants with acute moderate or severe infection with or without fever at the time of dosing
  • Participants who have had any suspected allergy symptoms, such as systemic rash, during the 72 hours before each administration of investigational product

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Srinagarind Hospital

Khon Kaen, Changwat Khon Kaen, Thailand, 40002

Actively Recruiting

Loading map...

Research Team

M

Minji Ko

CONTACT

S

Sujin Lee

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here